Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edap TMSFRA:EDA -0.95%59 Receivables Turnover is 0.88 as of Mar. 2026. GuruFocus rates FRA:EDA with a GF Score™ of 59/100 and a GF Value™ of €3.63 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 119 Medical Distribution companies, Edap TMS ranks better than 55.46% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Edap TMS's Revenue for the
three
months ended in Mar. 2026 was €15.41 Mil. Edap TMS's average Accounts Receivable for the
three
months ended in Mar. 2026 was €17.59 Mil.
Hence, Edap TMS's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.88.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Edap TMS Receivables Turnover Related Terms
Edap TMS Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Edap TMS's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:EDA vs ACH, YI, COSM: Receivables Turnover Comparison
For the Medical Distribution subindustry, Edap TMS's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edap TMS Receivables Turnover vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Edap TMS's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Edap TMS's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edap TMS (FRA:EDA) has a Receivables Turnover of 0.88 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Edap TMS and its competitors. According to the industry distribution chart, Edap TMS ranks #53 out of 119 companies in the Medical Distribution industry, placing it in the top 44.5%.
Is Edap TMS's Receivables Turnover too high?
Edap TMS's current Receivables Turnover is 0.88. The Medical Distribution industry median Receivables Turnover is 4.55. Edap TMS's value of 0.88 is 80.7% below this industry median. Based on the distribution chart, Edap TMS ranks #53 out of 119 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Edap TMS has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Edap TMS's Receivables Turnover compare to ACH and YI?
According to the Medical Distribution industry distribution chart, Edap TMS ranks #53 out of 119 companies for Receivables Turnover. This puts Edap TMS in the upper half of its industry. The industry median Receivables Turnover is 4.55. Edap TMS's value of 0.88 is 80.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Distribution company?
The median Receivables Turnover among Medical Distribution companies is 4.55, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edap TMS's current Receivables Turnover of 0.88 is 80.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Edap TMS and its competitors. For the Medical Distribution industry, the median Receivables Turnover is 4.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edap TMS's current Receivables Turnover is 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edap TMS stock overvalued right now?
Based on GuruFocus' analysis, Edap TMS (FRA:EDA) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.63, compared to a current price of €5.20 — trading 43.3% above its estimated fair value. The current Receivables Turnover is 0.88 and 80.7% below the Medical Distribution industry median of 4.55. Edap TMS's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Edap TMS (FRA:EDA), the current Receivables Turnover is 0.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edap TMS (FRA:EDA) Overvalued in 2026?
Based on GuruFocus' analysis, Edap TMS stock appears to be overvalued.
The current stock price of €5.20 is trading 43.3% above its estimated GF Value™ of €3.63.
GuruFocus considers Edap TMS to be Significantly Overvalued.
Key valuation signals for FRA:EDA:
Receivables Turnover: 0.88
GF Value™: €3.63 vs. price of €5.20 (43.3% above fair value)
Industry Position: 80.7% below the Medical Distribution median (#53 of 119)
No single metric tells the full story. See the FRA:EDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
59GF Score
Get the complete analysis for FRA:EDA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EDA has been successfully added to your 
